Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review

Maneeton, Benchalak; Maneeton, Narong; Likhitsathian, Surinporn; Woottiluk, Pakapan; Wiriyacosol, Punjaree; Boonyanaruthee, Vudhichai; Srisurapanont, Manit

doi:10.2147/ndt.s152410

Cited by 6 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTh is an effective treatment that has produced substantial outcomes [39]. Antidepressants worked effectively to treat patients with a depressed mood and suicidal potential [40]. Antidepressant drugs are primarily used to treat MDD-m, focusing on managing patients' depressive symptoms and enabling them to perform better life functions [41].…”

Section: Interventions Pharmacotherapy (Pth)mentioning

confidence: 99%

WITHDRAWN: Cognitive Behavior Therapy (CBT), Islam-Based Interventions (IBIs) and Pharmacotherapy (PTh) for Patients with Major Depressive Disorder-Mild (MDD-m): A Randomized Control Trial

Abbas

Shahbaz

Rauf³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Major depressive disorders (MDD) is common worldwide, and it causes significant functional impairment. Evidence-based therapies significantly address MDD symptoms severity; therefore, we aimed to investigate the effectiveness of pharmacotherapy (PTh), cognitive behaviour therapy (CBT), and Islam-based interventions (IBIs) to treat symptoms severity of patients MDD-m. Methods: This RCT was conducted by the Department of Applied Psychology, Government College University Faisalabad, from December 20, 2020, to October 31, 2021, at different hospitals in Faisalabad, Pakistan. Patients with MDD-m were allocated to three different evidence-based treatment approaches (i.e. PTh, CBT, & IBIs). Patients Health Questionnaire; Positive & Negative Affect Scale, Digit Span Scale, Standard Progressive Matrices, Self-Esteem Scale and Decision-Making Questionnaire were administered. SPSS version 27 was used to analyze the data. Results: A total of 210 were approached, 159 were assessed for eligibility, and 118 met the inclusion criteria, including males 66(55.94%) and females 52(44.06%) with the age range of 22 to 46 years. Findings reported all the treatment interventions produced significant treatment outcomes to reduce the depressive symptoms and improve memory, reasoning ability, decision-making skills, self-esteem, and wellbeing. PTh was an effective supportive intervention, while CBT and IBIs played an effective role as reeducative constructive therapies. Conclusion: All three interventions seem to be effective for major depressive disorder with mild severity, and CBT and IBIs emerged as more efficient and constructive therapies for MDD-m.

show abstract

Section: Interventions Pharmacotherapy (Pth)mentioning

confidence: 99%

WITHDRAWN: Cognitive Behavior Therapy (CBT), Islam-Based Interventions (IBIs) and Pharmacotherapy (PTh) for Patients with Major Depressive Disorder-Mild (MDD-m): A Randomized Control Trial

Abbas

Shahbaz

Rauf³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Major depressive disorder (MDD) is a recurrent, chronic mental illness and negatively impacts functioning and quality of life [ 1 ]. Although several antidepressants have displayed their efficacy in treatment in most of the MDD patients, including the first episode, [ 2 , 3 ] the delayed pharmacological antidepressant effects for the maximal or optimal improvement may require 6 to 12 weeks after administration, while some, including acutely suicidal patients, need a rapid response [ 4 ]. Additionally the delayed onset effect in MDD treatment is associated with several difficulties, including disability, reduced adherence to treatment, patient and family distress, economic consequences and increasing risk of suicidality [ 5 - 9 ].…”

Section: Introductionmentioning

confidence: 99%

Repetitive Transcranial Magnetic Stimulation Combined with Antidepressants for the First Episode of Major Depressive Disorder

Maneeton

Woottiluk

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objectives: The aims of this study were to systematically review the efficacy, acceptability and tolerability of repetitive transcranial magnetic stimulation (rTMS) combined with antidepressants in the treatment of the first major depressive disorder (MDD) episode. Materials and methods: The primary efficacious outcome was the pooled mean endpoint scores of the Hamilton Depression Rating scale (HAMD). Rates of response, remission rate, overall discontinuation and discontinuation due to adverse events were also evaluated. Searching in the Scopus, PubMed, CINAHL and Cochrane Controlled Trials Register databases for the interesting outcomes was carried out in March 2018. Results: A total of 108 randomized patients of two randomized controlled trials were included in this study. The pooled mean- endpoint scores of the HAMD in one, two, and four weeks for rTMS plus antidepressants (citalopram or paroxetine) were greater than that of sham plus the antidepressants. The pooled rates of overall discontinuation and discontinuation rates due to adverse events were not different between the two groups. Conclusion: According to a limited evidence, the high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) could accelerate the antidepressant effect of SSRIs in young patients with a first-episode major depressive disorder. However, the acceptability and tolerability of HF-rTMS in the treatment of such patients is no better than an antidepressant alone. However, further well-defined and large sample-size studies of HF-rTMS combined with antidepressant in MDD should be carried out to warrant these results.

show abstract

“…A 2018 meta-analysis of three RCTs (N=1,120) compared the efficacy and tolerability of duloxetine with escitalopram in the treatment of MDD. 2 Patients were adults with MDD diagnosed using Diagnostic and Statistical Manual version IV or IV-TR criteria, and all had a score of 22 or higher on the MADRS. All patients were treated with an eight-week regimen of either 10 to 20 mg escitalopram or 60 to 120 mg duloxetine.…”

mentioning

confidence: 99%

Is a serotonin–norepinephrine reuptake inhibitor superior to an SSRI in the treatment of major depressive disorder in adults?

Geschwind

Power

2021

EBPR

View full text Add to dashboard Cite

severe cellulitis of the extremities. Patients were excluded if they had lesions involving the trunk or neck, or if they had previously received antibiotics or wound debridement. Study endpoint was hospital discharge. Patients were further excluded from the study if they were discharged in less than 48 hours or if infection was mild enough to be treated with oral antibiotics before 48 hours. Necrotizing fasciitis was confirmed by operative findings and histopathology. Severe cellulitis was presumed where parenteral antibiotics were required for greater than 48 hours or when an abscess requiring debridement was present. A total of 825 patients met the criteria for severe cellulitis and 106 had pathology-proven necrotizing fasciitis.A LRINEC score was calculated for all patients included in the study with LRINEC scores greater than or equal to six having a sensitivity of 43% (95% CI, 0.34-0.53), a specificity of 83% (95% CI, 0.80-0.86), LR+ of 2.5, and LR2 of 0.69. For LRINEC scores greater than or equal to eight, sensitivity decreased to 27% (95% CI, 0.19-0.37), specificity increased to 93% (95% CI, 0.91-0.94), with LR+ of 3.9 and LR2 was 0.78. LRINEC showed poor performance with area under the receiveroperating characteristic curve for accuracy of 0.7 (95% CI, 0.64-0.75). This single-center study lacked confirmatory testing for severe cellulitis and limited evaluation to the extremities, reducing its generalizability.

show abstract

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review

Cited by 6 publications

References 23 publications

WITHDRAWN: Cognitive Behavior Therapy (CBT), Islam-Based Interventions (IBIs) and Pharmacotherapy (PTh) for Patients with Major Depressive Disorder-Mild (MDD-m): A Randomized Control Trial

WITHDRAWN: Cognitive Behavior Therapy (CBT), Islam-Based Interventions (IBIs) and Pharmacotherapy (PTh) for Patients with Major Depressive Disorder-Mild (MDD-m): A Randomized Control Trial

Repetitive Transcranial Magnetic Stimulation Combined with Antidepressants for the First Episode of Major Depressive Disorder

Is a serotonin–norepinephrine reuptake inhibitor superior to an SSRI in the treatment of major depressive disorder in adults?

Contact Info

Product

Resources

About